KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Equity Income: 2020-2023

Historic Equity Income for BeOne Medicines (ONC) over the last 4 years, with Dec 2023 value amounting to -$3.9 million.

  • BeOne Medicines' Equity Income rose 29.29% to -$3.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$16.2 million, marking a year-over-year increase of 26.25%. This contributed to the annual value of -$16.2 million for FY2023, which is 26.25% up from last year.
  • BeOne Medicines' Equity Income amounted to -$3.9 million in Q4 2023, which was up 60.89% from -$10.1 million recorded in Q3 2023.
  • BeOne Medicines' Equity Income's 5-year high stood at $23.2 million during Q3 2021, with a 5-year trough of -$17.0 million in Q1 2022.
  • Its 3-year average for Equity Income is -$2.5 million, with a median of -$3.6 million in 2021.
  • Within the past 5 years, the most significant YoY rise in BeOne Medicines' Equity Income was 2,313.65% (2021), while the steepest drop was 11,665.22% (2021).
  • Over the past 4 years, BeOne Medicines' Equity Income (Quarterly) stood at $1.9 million in 2020, then slumped by 614.79% to -$9.5 million in 2021, then skyrocketed by 41.44% to -$5.6 million in 2022, then increased by 29.29% to -$3.9 million in 2023.
  • Its Equity Income stands at -$3.9 million for Q4 2023, versus -$10.1 million for Q3 2023 and -$2.0 million for Q2 2023.